247 related articles for article (PubMed ID: 20473905)
1. Enhancement of NK cell antitumor responses using an oncolytic parvovirus.
Bhat R; Dempe S; Dinsart C; Rommelaere J
Int J Cancer; 2011 Feb; 128(4):908-19. PubMed ID: 20473905
[TBL] [Abstract][Full Text] [Related]
2. NK-cell-dependent killing of colon carcinoma cells is mediated by natural cytotoxicity receptors (NCRs) and stimulated by parvovirus infection of target cells.
Bhat R; Rommelaere J
BMC Cancer; 2013 Jul; 13():367. PubMed ID: 23902851
[TBL] [Abstract][Full Text] [Related]
3. SMAD4: a predictive marker of PDAC cell permissiveness for oncolytic infection with parvovirus H-1PV.
Dempe S; Stroh-Dege AY; Schwarz E; Rommelaere J; Dinsart C
Int J Cancer; 2010 Jun; 126(12):2914-27. PubMed ID: 19856310
[TBL] [Abstract][Full Text] [Related]
4. Activation of the human immune system via toll-like receptors by the oncolytic parvovirus H-1.
Sieben M; Schäfer P; Dinsart C; Galle PR; Moehler M
Int J Cancer; 2013 Jun; 132(11):2548-56. PubMed ID: 23151948
[TBL] [Abstract][Full Text] [Related]
5. Antitumoral activity of parvovirus-mediated IL-2 and MCP-3/CCL7 delivery into human pancreatic cancer: implication of leucocyte recruitment.
Dempe S; Lavie M; Struyf S; Bhat R; Verbeke H; Paschek S; Berghmans N; Geibig R; Rommelaere J; Van Damme J; Dinsart C
Cancer Immunol Immunother; 2012 Nov; 61(11):2113-23. PubMed ID: 22576056
[TBL] [Abstract][Full Text] [Related]
6. Activation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus H-1.
Moehler M; Sieben M; Roth S; Springsguth F; Leuchs B; Zeidler M; Dinsart C; Rommelaere J; Galle PR
BMC Cancer; 2011 Oct; 11():464. PubMed ID: 22029859
[TBL] [Abstract][Full Text] [Related]
7. Immune cells participate in the oncosuppressive activity of parvovirus H-1PV and are activated as a result of their abortive infection with this agent.
Grekova S; Aprahamian M; Giese N; Schmitt S; Giese T; Falk CS; Daeffler L; Cziepluch C; Rommelaere J; Raykov Z
Cancer Biol Ther; 2010 Dec; 10(12):1280-9. PubMed ID: 21124075
[TBL] [Abstract][Full Text] [Related]
8. Interferon γ improves the vaccination potential of oncolytic parvovirus H-1PV for the treatment of peritoneal carcinomatosis in pancreatic cancer.
Grekova SP; Aprahamian M; Daeffler L; Leuchs B; Angelova A; Giese T; Galabov A; Heller A; Giese NA; Rommelaere J; Raykov Z
Cancer Biol Ther; 2011 Nov; 12(10):888-95. PubMed ID: 22024742
[TBL] [Abstract][Full Text] [Related]
9. Human Retrotransposons and the Global Shutdown of Homeostatic Innate Immunity by Oncolytic Parvovirus H-1PV in Pancreatic Cancer.
Neulinger-Muñoz M; Schaack D; Grekova SP; Bauer AS; Giese T; Salg GA; Espinet E; Leuchs B; Heller A; Nüesch JPF; Schenk M; Volkmar M; Giese NA
Viruses; 2021 May; 13(6):. PubMed ID: 34071585
[TBL] [Abstract][Full Text] [Related]
10. Dual effects of cytokines in regulation of MHC-unrestricted cell mediated cytotoxicity.
Reiter Z
Crit Rev Immunol; 1993; 13(1):1-34. PubMed ID: 8466640
[TBL] [Abstract][Full Text] [Related]
11. Combined oncolytic and vaccination activities of parvovirus H-1 in a metastatic tumor model.
Raykov Z; Grekova S; Galabov AS; Balboni G; Koch U; Aprahamian M; Rommelaere J
Oncol Rep; 2007 Jun; 17(6):1493-9. PubMed ID: 17487410
[TBL] [Abstract][Full Text] [Related]
12. Complementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancer.
Angelova AL; Grekova SP; Heller A; Kuhlmann O; Soyka E; Giese T; Aprahamian M; Bour G; Rüffer S; Cziepluch C; Daeffler L; Rommelaere J; Werner J; Raykov Z; Giese NA
J Virol; 2014 May; 88(10):5263-76. PubMed ID: 24574398
[TBL] [Abstract][Full Text] [Related]
13. Parvovirus H1 selectively induces cytotoxic effects on human neuroblastoma cells.
Lacroix J; Leuchs B; Li J; Hristov G; Deubzer HE; Kulozik AE; Rommelaere J; Schlehofer JR; Witt O
Int J Cancer; 2010 Sep; 127(5):1230-9. PubMed ID: 20087864
[TBL] [Abstract][Full Text] [Related]
14. Improved killing of human high-grade glioma cells by combining ionizing radiation with oncolytic parvovirus H-1 infection.
Geletneky K; Hartkopf AD; Krempien R; Rommelaere J; Schlehofer JR
J Biomed Biotechnol; 2010; 2010():350748. PubMed ID: 20224643
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic implications of the enhanced short and long-term cytotoxicity of radiation treatment followed by oncolytic parvovirus H-1 infection in high-grade glioma cells.
Geletneky K; Hartkopf AD; Krempien R; Rommelaere J; Schlehofer JR
Bioeng Bugs; 2010; 1(6):429-33. PubMed ID: 21468212
[TBL] [Abstract][Full Text] [Related]
16. Defective Localization With Impaired Tumor Cytotoxicity Contributes to the Immune Escape of NK Cells in Pancreatic Cancer Patients.
Lim SA; Kim J; Jeon S; Shin MH; Kwon J; Kim TJ; Im K; Han Y; Kwon W; Kim SW; Yee C; Kim SJ; Jang JY; Lee KM
Front Immunol; 2019; 10():496. PubMed ID: 31024520
[TBL] [Abstract][Full Text] [Related]
17. Preclinical Testing of an Oncolytic Parvovirus in Ewing Sarcoma: Protoparvovirus H-1 Induces Apoptosis and Lytic Infection In Vitro but Fails to Improve Survival In Vivo.
Lacroix J; Kis Z; Josupeit R; Schlund F; Stroh-Dege A; Frank-Stöhr M; Leuchs B; Schlehofer JR; Rommelaere J; Dinsart C
Viruses; 2018 Jun; 10(6):. PubMed ID: 29865280
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C virus-infected cells downregulate NKp30 and inhibit ex vivo NK cell functions.
Holder KA; Stapleton SN; Gallant ME; Russell RS; Grant MD
J Immunol; 2013 Sep; 191(6):3308-18. PubMed ID: 23960237
[TBL] [Abstract][Full Text] [Related]
19. Anergic natural killer cells educated by tumor cells are associated with a poor prognosis in patients with advanced pancreatic ductal adenocarcinoma.
Yang C; Cheng H; Zhang Y; Fan K; Luo G; Fan Z; Huang Q; Lu Y; Jin K; Wang Z; Yu X; Liu C
Cancer Immunol Immunother; 2018 Dec; 67(12):1815-1823. PubMed ID: 30167864
[TBL] [Abstract][Full Text] [Related]
20. Reciprocal human dendritic cell-natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirus.
Prestwich RJ; Errington F; Steele LP; Ilett EJ; Morgan RS; Harrington KJ; Pandha HS; Selby PJ; Vile RG; Melcher AA
J Immunol; 2009 Oct; 183(7):4312-21. PubMed ID: 19734207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
